ZYPITAMAG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZYPITAMAG (ZYPITAMAG).
ZYPITAMAG (pitavastatin magnesium) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced intracellular cholesterol and upregulation of LDL receptors.
| Metabolism | Primarily hepatic via glucuronidation (major) and CYP2C9 (minor); not significantly metabolized by CYP3A4. |
| Excretion | Primarily renal (93% as unchanged pitavastatin and metabolites) via active tubular secretion; fecal (5%) |
| Half-life | Terminal elimination half-life: 12 hours (range 10-14 h) in healthy subjects; supports once-daily dosing |
| Protein binding | >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Mean Vd: 0.5 L/kg (approx 35 L in 70 kg adult); indicates distribution primarily into extracellular fluid and tissues |
| Bioavailability | Oral bioavailability: 51% (absolute); absorption increased with food (no significant effect on AUC) |
| Onset of Action | Oral: onset of LDL-C reduction observed within 1 week of daily dosing; maximal effect by 4 weeks |
| Duration of Action | Duration of LDL-C reduction persists with continued daily dosing; steady-state achieved in 4-5 days; lipid effects maintained over 24-hour dosing interval |
2-4 mg orally once daily, at any time of day, with or without food.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Avoid use in severe renal impairment (CrCl <30 mL/min) or in patients on hemodialysis. |
| Liver impairment | Contraindicated in active liver disease or unexplained persistent elevations of hepatic transaminases. No specific Child-Pugh-based adjustments; use caution in patients with mild hepatic impairment. |
| Pediatric use | Not approved for use in pediatric patients. Safety and efficacy in children have not been established. |
| Geriatric use | No specific dose adjustment required; use the standard adult dose. Monitor for adverse effects, as elderly patients may be more susceptible to myopathy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZYPITAMAG (ZYPITAMAG).
| Breastfeeding | Pitavastatin is excreted in human milk; M/P ratio not established. Due to potential for serious adverse effects in nursing infants (e.g., interference with lipid metabolism), breastfeeding is not recommended during therapy. Alternative agents with established safety profiles should be considered. |
| Teratogenic Risk | Zypitamag (pitavastatin) is contraindicated in pregnancy. Statins are associated with fetal harm due to inhibition of HMG-CoA reductase, essential for cholesterol synthesis. First trimester exposure may increase risk of congenital anomalies (e.g., CNS, limb defects). Second and third trimester exposure risks include fetal growth restriction, low birth weight, and potential developmental toxicity. Pregnancy category: X (FDA). |
■ FDA Black Box Warning
Increases in HbA1c and fasting serum glucose levels have been reported; no explicit boxed warning exists.
| Serious Effects |
["Active liver disease or unexplained persistent elevations in hepatic transaminases","Pregnancy and breastfeeding","Known hypersensitivity to any component of ZYPITAMAG","Concomitant administration with cyclosporine"]
| Precautions | ["Skeletal muscle effects: rhabdomyolysis with renal dysfunction; discontinue if markedly elevated CPK or myopathy suspected","Hepatic effects: persistent elevations in serum transaminases; perform liver function tests before initiation and thereafter as clinically indicated","Endocrine effects: increases in HbA1c and fasting glucose; may require adjustment of hypoglycemic therapy"] |
Loading safety data…
| Fetal Monitoring | Monitor hepatic function tests (ALT, AST) periodically due to risk of hepatotoxicity. Assess lipid profile to evaluate therapeutic efficacy. In cases of accidental exposure during pregnancy, perform fetal ultrasound to evaluate for congenital anomalies. Monitor maternal creatine kinase if muscle symptoms occur. No specific fetal monitoring is routinely recommended for statin use in pregnancy as it is contraindicated. |
| Fertility Effects | No definitive human studies on fertility. Animal studies showed no significant impairment of fertility at clinically relevant doses. Statins may theoretically affect steroid hormone synthesis, but clinical relevance is uncertain. In males, possible effects on sperm parameters have not been rigorously studied. Advise patients of unknown risks and discuss alternative therapies if fertility is a concern. |